Cellectis (CLLS) Liabilities from Discontinued Operations (2022 - 2023)
Cellectis (CLLS) posted quarterly Liabilities from Discontinued Operations of 17328000.0 for Q1 2023, up 16.58% quarter-over-quarter from 14864000.0 in Q4 2022.
Powered by 
Analysis
Cellectis (CLLS) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends
Cellectis' Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 17328000.0 for Q1 2023.
- In Q1 2023, Liabilities from Discontinued Operations changed N/A year-over-year to 17328000.0; the TTM figure through Mar 2023 stood at 17328000.0 (changed N/A YoY), while the FY2022 annual figure was 14864000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2023 stood at 17328000.0, up from 14864000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 17328000.0 in Q1 2023, with the low at 14864000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |